Leena Gandhi, MD, PhD, has been named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway.
Dr. Gandhi joins NextPoint from the Dana Farber Cancer Institute in Boston, according to a Feb. 21 news release. While at Dana Farber, she served as director of the Center for Cancer Therapeutic Innovation.
Dr. Gandhi has also served as vice president of immuno-oncology development at pharmaceutical company Eli Lilly and director of thoracic medical oncology at New York University.